Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

High quality 3d render of nerve cells, concept for Neurologic Diseases, tumors and brain surgery.
Alnylam presented 18-month data from the HELIOS-A study of vutrisiran in hATTR amyloidosis with polyneuropathy • Source: Shutterstock

Alnylam Pharmaceuticals Inc. anticipates its drug vutrisiran will take a bigger chunk of the market for hereditary transthyretin-mediated (hATTR) amyloidosis after presenting long-term data in patients with polyneuropathy. The new 18-month data should also fulfill the requirements for the company to file for European Medicines Agency approval, whereas the drug is already under US Food and Drug Administration review based on 9-month data.

On 21 January, Alnylam presented 18-month data from the Phase III HELIOS-A study of vutrisiran at the Société Francophone du...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By 

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Post-BIO Podcast: Thoughts From The Frontlines

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.